Priya Marreddy
Directeur Technique/Scientifique/R&D chez CONTEXT THERAPEUTICS INC.
Profil
Priya Marreddy is currently the Vice President-Clinical Operations at Context Therapeutics, Inc. Previously, she worked as the Head-Clinical Operations at Cornerstone Pharmaceuticals, Inc. She completed her graduate degree at the University of Pennsylvania and her undergraduate degree at George Washington University.
Postes actifs de Priya Marreddy
| Sociétés | Poste | Début |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/04/2022 |
Anciens postes connus de Priya Marreddy
| Sociétés | Poste | Fin |
|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Directeur Technique/Scientifique/R&D | - |
Formation de Priya Marreddy
| George Washington University | Undergraduate Degree |
| University of Pennsylvania | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |